Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Arthur C. Fleischer, MD
Vanderbilt-Ingram Cancer Center
Study Chair - David Fishman, MD
Icahn School of Medicine at Mount Sinai
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2007
- Primary completion
- 29 Feb 2012
- Completion
- 29 Feb 2012
- Last update posted
- 18 Apr 2017
- Registered enrollment
- 67
- Registry id
- NCT00626873
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.